Carfilzomib and dexamethasone vs bortezomib and dexamethasone
in patients with relapsed multiple myeloma: results of the
phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

J 2017

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

LUDWIG, H.; M.A. DIMOPOULOS; P. MOREAU; W.J. CHNG; H. GOLDSCHMIDT et. al.

Základní údaje

Originální název

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Autoři

Vydání

LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2017, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.644

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1080/10428194.2017.1298755

UT WoS

000404572000031

Klíčová slova anglicky

Carfilzomib; dexamethasone; bortezomib

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 16. 3. 2018 15:00, Soňa Böhmová

Anotace

V originále

Article Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

Citovat

LUDWIG, H.; M.A. DIMOPOULOS; P. MOREAU; W.J. CHNG; H. GOLDSCHMIDT; Roman HÁJEK; T. FACON; Luděk POUR; R. NIESVIZKY; A. ORIOL; L. ROSINOL; A. SUVOROV; G. GAIDANO; T. PIKA; K. WEISEL; V. GORANOVA-MARINOVA; A. PALUMBO; H.H. GILLENWATER; N. MOHAMED; S. AGGARWAL; S.B. FENG a D. JOSHUA. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2017, roč. 58, č. 10, s. 2501-2504. ISSN 1042-8194. Dostupné z: https://doi.org/10.1080/10428194.2017.1298755.

@article{1398977,
   author = {Ludwig, H. and Dimopoulos, M.A. and Moreau, P. and Chng, W.J. and Goldschmidt, H. and Hájek, Roman and Facon, T. and Pour, Luděk and Niesvizky, R. and Oriol, A. and Rosinol, L. and Suvorov, A. and Gaidano, G. and Pika, T. and Weisel, K. and GoranovaandMarinova, V. and Palumbo, A. and Gillenwater, H.H. and Mohamed, N. and Aggarwal, S. and Feng, S.B. and Joshua, D.},
   article_location = {LONDON},
   article_number = {10},
   doi = {https://doi.org/10.1080/10428194.2017.1298755},
   keywords = {Carfilzomib; dexamethasone; bortezomib},
   language = {eng},
   issn = {1042-8194},
   journal = {LEUKEMIA & LYMPHOMA},
   title = {Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup},
   url = {http://dx.doi.org/10.1080/10428194.2017.1298755},
   volume = {58},
   year = {2017}
}

TY  - JOUR
ID  - 1398977
AU  - Ludwig, H. - Dimopoulos, M.A. - Moreau, P. - Chng, W.J. - Goldschmidt, H. - Hájek, Roman - Facon, T. - Pour, Luděk - Niesvizky, R. - Oriol, A. - Rosinol, L. - Suvorov, A. - Gaidano, G. - Pika, T. - Weisel, K. - Goranova-Marinova, V. - Palumbo, A. - Gillenwater, H.H. - Mohamed, N. - Aggarwal, S. - Feng, S.B. - Joshua, D.
PY  - 2017
TI  - Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
JF  - LEUKEMIA & LYMPHOMA
VL  - 58
IS  - 10
SP  - 2501-2504
EP  - 2501-2504
PB  - INFORMA HEALTHCARE
SN  - 10428194
KW  - Carfilzomib
KW  - dexamethasone
KW  - bortezomib
UR  - http://dx.doi.org/10.1080/10428194.2017.1298755
L2  - http://dx.doi.org/10.1080/10428194.2017.1298755
N2  - Article Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
ER  -

LUDWIG, H.; M.A. DIMOPOULOS; P. MOREAU; W.J. CHNG; H. GOLDSCHMIDT; Roman HÁJEK; T. FACON; Luděk POUR; R. NIESVIZKY; A. ORIOL; L. ROSINOL; A. SUVOROV; G. GAIDANO; T. PIKA; K. WEISEL; V. GORANOVA-MARINOVA; A. PALUMBO; H.H. GILLENWATER; N. MOHAMED; S. AGGARWAL; S.B. FENG a D. JOSHUA. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. \textit{LEUKEMIA \&{}amp; LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2017, roč.~58, č.~10, s.~2501-2504. ISSN~1042-8194. Dostupné z: https://doi.org/10.1080/10428194.2017.1298755.

Přehled o publikaci